381 related articles for article (PubMed ID: 30423357)
1. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
Binju M; Padilla MA; Singomat T; Kaur P; Suryo Rahmanto Y; Cohen PA; Yu Y
Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):371-378. PubMed ID: 30423357
[TBL] [Abstract][Full Text] [Related]
2. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
van Zyl B; Tang D; Bowden NA
Endocr Relat Cancer; 2018 May; 25(5):R303-R318. PubMed ID: 29487129
[TBL] [Abstract][Full Text] [Related]
4. Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
Havasi A; Cainap SS; Havasi AT; Cainap C
Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984544
[TBL] [Abstract][Full Text] [Related]
5. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
6. The Application of Biomaterials in the Treatment of Platinum-Resistant Ovarian Cancer.
Levy A; Leynes C; Baig M; Chew SA
ChemMedChem; 2019 Nov; 14(21):1810-1827. PubMed ID: 31456347
[TBL] [Abstract][Full Text] [Related]
7. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
8. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
9. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
[TBL] [Abstract][Full Text] [Related]
10. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
11. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
13. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
14. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
[TBL] [Abstract][Full Text] [Related]
15. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
16. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
17. Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index.
Hetland TE; Kærn J; Skrede M; Sandstad B; Tropé C; Davidson B; Flørenes VA
Cancer Chemother Pharmacol; 2012 May; 69(5):1307-14. PubMed ID: 22302409
[TBL] [Abstract][Full Text] [Related]
18. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer.
Colombo PE; Fabbro M; Theillet C; Bibeau F; Rouanet P; Ray-Coquard I
Crit Rev Oncol Hematol; 2014 Feb; 89(2):207-16. PubMed ID: 24071502
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
